Clinical Trial Detail

NCT ID NCT03367819
Title Isatuximab in Combination With REGN2810 in Patients With Advanced Malignancies
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors Sanofi
Indications

lung non-small cell carcinoma

prostate cancer

Therapies

Isatuximab

Cemiplimab + Isatuximab

Age Groups: adult senior

No variant requirements are available.